Why Ionis Pharmaceuticals, Inc. (IONS) stock moved
Updated Sep 9, 2026
Ionis Pharmaceuticals, Inc. (IONS) shares fell 2.4% to $56.71 as of September 9, 2026, a modest decline from the prior close of $58.09. BestStocks flagged the session as a major change for IONS. The move is tied to price move up. Below, we break down what changed for IONS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
IONS fell 2.4% to $56.71
IONS fell 2.4% in its latest session, moving from $58.09 to $56.71.
Material / EarningsMedium confidence
Rel. volume
3.4×
Extreme
Vs peers
—
No comparable peers
Market cap
$9.4B
NASDAQ Global Select
Analyst target
$87
+54.2% vs price
Price chart
Sep 9
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Ionis Pharmaceuticals, Inc. investors
For Ionis Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Material negative event; Negative session, down 2.4%. Wall Street's consensus price target sits at $87.42, implying +54.2% upside from $56.71. Over the past 90 days analysts logged 0 upgrades and 2 downgrades. BestStocks rates the overall signal quality medium (62/100). With earnings roughly 56 days out, the next report is the most likely near-term test of the move.
IONS price reaction
IONS last traded at $56.71, down $1.38 (-2.38%) from the previous close of $58.09. The session traded on 3.4× average volume (extreme), so the move carried above-average conviction.
Bullish and bearish analyst opinions on Ionis Pharmaceuticals, Inc. (IONS)
The consensus analyst price target on Ionis Pharmaceuticals, Inc. (IONS) is $87.42, 54.2% above the recent $56.71. Over the past 90 days analysts logged 0 upgrades, 26 maintains, and 2 downgrades. Here is how the bullish and bearish cases on IONS line up.
▲ The bullish case
+Wall Street's consensus price target of $87.42 implies +54.2% upside from $56.71.
+The Street's most bullish target is $115.00 (+102.8%).
+Positive price momentum.
▼ The bearish case
−The most bearish analyst target is $54.00 (-4.8%).
−2 analyst downgrades in the past 90 days, most recently BMO Capital to Market Perform (2026-08-19).
−Material negative event.
−Negative session, down 2.4%.
−High volume 3.4x on decline — distribution signal.
Bull vs bear balanceBearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 9, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Ionis Pharmaceuticals fell 3.95% to $55.79 intraday following the announcement that its Phase 3 pelacarsen cardiovascular outcome study (conducted with partner Novartis) missed its primary endpoint, per web sources. The stock has declined over 10% since the initial announcement on September 4, 2026, with elevated volume of 7.96x the time-adjusted average reflecting heightened selling pressure.
Ionis Pharmaceuticals fell 6.08% to $57.60 as investors reacted to a newly filed investor investigation by Pomerantz LLP and downgraded EPS forecasts from HC Wainwright, which projected higher quarterly losses through 2026 and 2027. The decline extends pressure from earlier setbacks including disappointing Phase 3 data for eplontersen and competition concerns. Volume of 2.55M shares traded at 1.30x the historical average for this point in the session.
Ionis Pharmaceuticals rose 2.97% to $63.88, driven by institutional buying and positive analyst sentiment ahead of the European Society of Cardiology (ESC) Congress. Canaccord reiterated a Buy rating with a $95 price target, BMO Capital Markets upgraded to Hold, and Piper Sandler reaffirmed Buy; firms including Connor Clark & Lunn Investment Management and Algert Global LLC initiated or expanded positions in the last 24–48 hours. Volume stood at 852,477 shares (120 min into session), tracking 1.13x normal for this time.
Ionis Pharmaceuticals rose 3.29% to $61.71, driven by recent institutional buying from Deutsche Bank, Globeflex Capital, and Polymer Capital Management, combined with positive analyst coverage from Piper Sandler and BMO Capital Markets following a summer decline. The move reflects recovering investor confidence after earlier setbacks, though intraday volume of 1.36M shares (0.59x the session average) suggests below-average participation.
Material / Earnings2026-08-18
Ionis Pharmaceuticals, Inc. (IONS) moved +2.35% from $58.25 to $59.62 on 2026-08-18, reaching a new 30-day high on modestly elevated volume (1.6x the 5-day average).
Material / Earnings2026-08-17
Ionis Pharmaceuticals, Inc. (IONS) moved +2.42% from $57.24 to $58.63 on 2026-08-17, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-14
Ionis Pharmaceuticals, Inc. (IONS) moved +3.41% from $55.35 to $57.24 on 2026-08-14, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Material / Earnings2026-08-12
Ionis Pharmaceuticals, Inc. (IONS) moved +2.76% from $55.01 to $56.53 on 2026-08-12. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
Upcoming catalysts & outlook
Next earnings
2026-11-04 (est.)
in 56 days
Earnings Release
2026-11-04
High impact
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events
Frequently asked questions about IONS
Why did Ionis Pharmaceuticals, Inc. (IONS) stock move?
IONS fell 2.4% to $56.71. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did IONS stock fall?
IONS lost 2.38% ($1.38) versus the prior close of $58.09, last trading at $56.71 on 3.4× average volume.
When is Ionis Pharmaceuticals, Inc.'s next earnings date?
IONS's next earnings report is estimated for 2026-11-04 — about 56 days away.
What is the analyst price target for IONS?
The consensus analyst price target for IONS is $87.42, about 54.2% above the current $56.71. Over the past 90 days, analysts recorded 0 upgrades, 26 maintains, and 2 downgrades.
How BestStocks tracks IONS
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for IONS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 9, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
